CME. Thoracic Malignancies. Annual Oncology Symposium: Friday, May 2, Glaser Auditorium Swedish/First Hill 747 Broadway Seattle, Washington

Transcription

1 Annual Oncology Symposium: Thoracic Malignancies CME CONTINUING MEDICAL EDUCATION Friday, May 2, 2014 Glaser Auditorium Swedish/First Hill 747 Broadway Seattle, Washington

2 Needs Statement The American Cancer Society s 2013 Cancer Facts & Figures estimated that 228,190 new cases of lung cancer (the most common type of thoracic cancer) were expected in This accounts for 14% of all cancer diagnoses. Though the incidence rate has begun to decline in the past few years, lung cancer still accounts for more deaths than any other cancer in both men and women and is the second overall leading cause of death in North America after heart disease. New improvements in radiation therapy platforms, surgical techniques, combined therapies and novelties in related fields have begun to improve survival rates; however, to continue to provide optimal, cohesive therapeutic care for thoracic cancer patients, it is necessary to rapidly disseminate knowledge of the latest advances to oncologists and other treating physicians and allied health professionals. Recent studies have shown that less than a quarter of patients diagnosed with localized lung cancer received testing in the guideline-recommended sequence, resulting in complications and unnecessary costs. Guidelineconsistent care is associated with better patient outcomes and fewer invasive tests. With lung cancer screening of high-risk patients becoming more common, it is essential for all treating physicians, including primary-care, to receive essential guidelines and recommendations to provide optimal patient care. National experts will present on the following topics where knowledge and competence are needed: lung cancer screening, small peripheral cancers, lung cancer in octogenarians, stage IV adeno carcinoma, immunotherapy, social media and cancer care, T4 spine/pancoast and modern palliation of lung cancer. Less common malignancies, arising from other intrathoracic organs such as the esophagus, the pleura or the thymus, will also be reviewed. Course Description Based on the target audience and the learners scope of practice, the goal of this symposium is to present a comprehensive approach to cancer treatment for patients with thoracic related malignancies. This multidisciplinary meeting will promote collaboration between surgery, medical oncology, radiation oncology and primary care to achieve the best possible outcome for thoracic cancer patients. Intended Audience This conference is targeted towards all health-care workers in the Northwest Region who treat patients suffering from thoracic malignancies. This includes physicians, nurses, allied health professionals and residents. It is especially relevant for primary-care, internal medicine, pulmonology, medical oncology, radiology oncology and surgery (working with thoracic patients). Accreditation Accreditation with Commendation Swedish Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. AMA PRA Category 1 Credits Swedish Medical Center designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AAFP Prescribed Credits Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending. Nursing CE Contact Hours Swedish Medical Center Clinical Education and Practice is an approved provider of continuing nursing education by the Washington State Nurses Association Continuing Education Approval & Recognition Program (CEARP), an accredited approver by the American Nurses Credentialing Center s Commission on Accreditation. Acknowledgments This symposium is financially supported in part by educational grants in accordance with ACCME s Standards for Commercial Support. At the time of this printing, a complete listing of commercial supporters was not available. Appropriate acknowledgment will be given to all supporters at the time of the symposium. Planning Committee, Course Co-Chair Eric Vallières, M.D., Course Co-Chair Caye Boosalis, MEd, CME Manager Joelle Thirsk Fathi, DNP, R.N., ARNP Jed Gorden, M.D. Kristin Manning, M.D. Becky Mann, MSN Vivek Mehta, M.D. Danielle Westley, CME Specialist

3 Agenda 7:30 a.m. Registration and Continental Breakfast 8 a.m. Welcome and Introductions Eric Vallières, M.D. and Lung Cancer I 8:10 a.m. Lung Cancer Screening: Current Status Ella A. Kazerooni, M.D., MS 8:40 a.m. Essential Components and Qualities of a Lung Cancer Screening Program Joelle Thirsk Fathi, DNP, R.N., ARNP Controversies in Small Non-Small Lung Cancer 8:55 a.m. Early Lung Cancer: Balancing Disease and Cure Ralph W. Aye, M.D., FACS 9:10 a.m. Assessing Survival: Grading the Severity of Complications in Octogenarians Undergoing Lobectomy Alexander S. Farivar, M.D. 9:25 a.m. Early Lung Cancer: Is it Time to Put Away the Knife and Use SBRT Instead of Surgery for All Patients? Vivek Mehta, M.D. 9:40 a.m. Panel: Case Presentations Ralph W. Aye, M.D., FACS; Alexander S. Farivar, M.D. and Vivek Mehta, M.D. 10 a.m. Break Lung Cancer II 10:15 a.m. Transitioning Survival from Months to Years in Advanced Non-small Cell Lung Cancer (NSCLC) 10:45 a.m. Immunotherapy for Lung Cancer David E. Gerber, M.D. 11:15 a.m. The Third Party in the Exam Room: Dr. Google and Online Patient Communities 11:30 a.m. Panel Discussion David E. Gerber, M.D. and 11:45 a.m. Lunch Locally Advanced NSCLC 12:30 p.m. T4 Spine Involvement/Pancoast Tumors Eric Vallières, M.D. 12:45 p.m. Preoperative Radiation Therapy in IIIA NSCLC: 45 vs. 60 Eric Vallières, M.D. with Vivek Mehta, M.D. 1 p.m. Palliation of Advanced Stage Lung Cancer Jed Gorden, M.D. Esophageal Cancer 1:15 p.m. Endoscopic Therapy 1:30 p.m. Multi-Modality Management of Esophageal Cancer Thomas D. Brown, M.D., MBA 1:45 p.m. Not All Esophagectomies Are Created Equal 2:05 p.m. Break Mediastinum and Pleura 2:20 p.m. Malignant Pleural Mesothelioma: What s New in 2014? Alexander S. Farivar, M.D. 2:40 p.m. Minimally Invasive Thymectomy 3 p.m. Cancer in the New Health-care World: Health Policy & Cost of Cancer Care David J. Stewart M.D., FRCPC 4 p.m. Adjourn Location Swedish Medical Center is located at 747 Broadway in Seattle, Washington. The conference will be held in the Glaser Auditorium on the first floor of the medical center. Parking is available in the Broadway Garage at 747 Broadway at a maximum fee of $15. From I-5 (northbound and southbound), take the James Street exit. Travel east on James Street. Turn left (north) onto Broadway. Turn left into the main hospital entrance and follow the signs to the Broadway underground parking garage.

4 Course Objectives At the conclusion of this symposium, the participant will provide better patient care through an increased ability to:det Review the current state of lung cancer screening with CT and determine who should be screened; discuss how CT exams should be performed and outline structured reporting and management recommendations for lung cancer screenings Identify the ideal setting for a lung cancer screening program, review the essential components of a lung cancer screening program and recognize the importance of screening in a structured setting Assess the risk of a lung nodule, review the role of imaging and biopsy of lung nodules and compare the treatment alternatives and outcomes for early lung cancer Discuss the percentage of patients under the age of 80 undergoing lobectomy that can be safely discharged home and review the five-year actuarial survival of octogenarians after lobectomy Review indications for stereotactic body radiation therapy (SBRT), discuss various SBRT treatment approaches and identify appropriate patients for SBRT Describe new histologic and molecular variables for dividing patients with advanced non-small cell lung cancer (NSCLC) into subgroups with distinct optimal treatment pathways and prognosis; discuss the targeted therapies, both approved and being studied, that have demonstrated significant improvements in clinical outcomes for patients with identified driver mutations and evaluate the utility of specific chemotherapy agents and erlotinib for distinct clinical populations that do not have an identified driver mutation List the components of anti-tumor immunity, compare immunotherapy-based treatment strategies for lung cancer and review recent clinical experience with immunotherapy for lung cancer treatment Recognize the shifting dynamic of the doctor/patient relationship introduced by the rapid acceleration of new medical information and availability of medical content online; identify ways in which health-care professionals can use online communities and social media to counteract misinformation and increase dissemination of high quality medical information and utilize new models of clinical research that leverage online communication to facilitate trial enrollment, particularly for small, geographically diverse subgroups Review the surgical principles to the complex resection of NSCLC with direct central skeletal involvement and discuss the rationale and data that supports a combined modality approach to Pancoast tumors Compare the benefits and differences of the various preoperative radiation strategies in the management of surgical stage IIIA N2 NSCLC and utilize the possible management strategies of IIIA N2 NSCLC Review the importance of a palliative strategy for patients with advanced state disease and discuss the importance of palliation of symptomatic pleural disease and central airway obstruction on patient quality of life and maintenance of independence Discuss the role of endoscopic therapy in early esophageal cancer, list the indications for endoscopic therapy and review the current outcomes of endoscopic therapy for early esophageal cancer Review multimodality curative strategies for esophageal cancer, discuss associated toxicities and compare quality of life and cost effectiveness aspects of esophageal cancer Describe the types of esophageal resection and review the outcomes, including long-term survival, for each type of esophageal resection Decide whether patients undergoing pleurectomy/ decortication should undergo radiation as part of their treatment plan and discuss which modalities should be considered first-line for patients undergoing EPP as part of trimodality therapy for mesothelioma Review the indications for a minimally invasive thymectomy and discuss the outcomes of minimally invasive thymectomy Compare the cost vs. benefits of cancer clinical research regulation; assess methods to improve costeffectiveness of clinical research regulation; discuss why personalization of lung cancer care is essential from the perspective of quality, efficacy and cost-effectiveness of care and discuss why new clinical research structures and methods are essential in the new era of molecular medicine For Further Information: Phone: Fax: CME@swedish.org Web:

5 Annual Oncology Symposium: Thoracic Malignancies Faculty Ralph W. Aye, M.D., FACS Thoracic and Foregut Surgery Clinical Program Leader Thoracic Oncology Fellowship Director Swedish Medical Center and Thomas D. Brown, M.D., MBA Executive Director Alexander S. Farivar, M.D. Thoracic Surgery Joelle Thirsk Fathi, DNP, R.N., ARNP Swedish Tobacco Related Diseases and Lung Cancer Screening Program A Division of Thoracic Surgery Clinical Assistant Professor Graduate School of Nursing University of Washington David E. Gerber, M.D. Associate Professor of Internal Medicine (Hematology- Oncology) Co-Director Lung Disease Oriented Team Co-Leader Experimental Therapeutics Program Harold C. Simmons Cancer Center University of Texas Southwestern Medical Center Jed Gorden, M.D. Medical Director Center for Pleural Diseases Director Interventional Pulmonology Division of Thoracic Surgery Ella A. Kazerooni, M.D., M.S. Professor of Radiology Associate Chair for Clinical Affairs Director of Cardiothoracic Radiology Department of Radiology University of Michigan Medical School Co-Director Minimally Invasive Thoracic Surgery Program Clinical Instructor General Surgery Residency Program Swedish Medical Center Thoracic & Esophageal Surgeon Director Research and Education Division of Thoracic Surgery Vivek Mehta, M.D. Radiation Oncologist Director for Center of Advanced Targeted Radiation Therapies David J. Stewart, M.D., FRCPC Chief and Head of Division of Medical Oncology Professor of Medicine University of Ottawa and The Ottawa Hospital Eric Vallières, M.D. Surgical Director Lung Cancer Program Medical Director Division of Thoracic Surgery Medical Oncologist Medical Director Thoracic Oncology Program

6 Registration Information: Preregistration is required as space is limited. Participants who register by the Advance Registration deadline will receive a confirmation postcard after Monday, April 21, Registrations will only be processed when accompanied by full payment. Cancellation: To receive a refund, notice of cancellation must be received no later than Friday, April 25, If using the registration form, please mail or fax it to: Continuing Medical Education Swedish Medical Center 747 Broadway Seattle, WA Fax: Please note: No registrations are accepted by phone or . If you have special needs, please contact the CME office at R E G I S T R A T I O N Annual Oncology Symposium: Thoracic Malignancies Friday, May 2, 2014 Please print or type information NAME ADDRESS CITY/STATE/ZIP PHONE EMERGENCY CONTACT NAME AND PHONE NUMBER FAX F O R M TITLE/CREDENTIALS SPECIALTY Save time register online! Registration Fees: Please check one of the following: Advance Registration After April 21 M.D. or D.O. $225 $255 Allied Health Professional $110 $140 Medical Student $25 $55 Resident or Fellow $25 $55 Payment: Check enclosed, payable to: Swedish CME Credit card # VISA MasterCard Discover AMEX Signature Expiration date PLEASE DETACH